-
EP4001273
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4001273
| EP4001273 - AMINOPYRIMIDINES AS ALK INHIBITORS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 07.07.2023 Database last updated on 22.05.2024 | |
| Former | The application has been published Status updated on 22.04.2022 | Most recent event Tooltip | 07.07.2023 | Application deemed to be withdrawn | published on 09.08.2023 [2023/32] | Applicant(s) | For all designated states The Regents Of The University Of Michigan Office Of Technology Transfer 1600 Huron Parkway, 2nd Floor Ann Arbor, MI 48109-2590 / US | [2022/21] | Inventor(s) | 01 /
Wang, Shaomeng Superior Township, 48198 / US | 02 /
Chen, Jianyong Ann Arbor, 48105 / US | [2022/21] | Representative(s) | Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW / GB | [N/P] |
| Former [2022/21] | McNab, Donald C. Marks & Clerk LLP 40 Torphichen Street Edinburgh EH3 8JB / GB | Application number, filing date | 21212760.9 | 28.08.2017 | [2022/21] | Priority number, date | US201662380818P | 29.08.2016 Original published format: US 201662380818 P | [2022/21] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP4001273 | Date: | 25.05.2022 | Language: | EN | [2022/21] | Type: | A3 Search report | No.: | EP4001273 | Date: | 24.08.2022 | Language: | EN | [2022/34] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 22.07.2022 | Classification | IPC: | C07D405/14, C07D401/12, A61K31/506, A61P35/00, A61P29/00, A61P37/00 | [2022/21] | CPC: |
A61K31/506 (EP,IL,KR,US);
C07D401/12 (EP,CN,IL,KR,US);
C07D405/14 (EP,CN,IL,KR,US);
A61P29/00 (CN);
A61P35/00 (EP,CN,IL,KR,US);
A61P37/00 (CN)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/21] | Title | German: | AMINOPYRIMIDINE ALS ALK-HEMMER | [2022/21] | English: | AMINOPYRIMIDINES AS ALK INHIBITORS | [2022/21] | French: | AMINOPYRIMIDINES EN TANT QU'INHIBITEURS D'ALK | [2022/21] | Examination procedure | 25.02.2023 | Application deemed to be withdrawn, date of legal effect [2023/32] | 21.03.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2023/32] | Parent application(s) Tooltip | EP17764949.8 / EP3504203 | Fees paid | Renewal fee | 07.12.2021 | Renewal fee patent year 03 | 07.12.2021 | Renewal fee patent year 04 | 07.12.2021 | Renewal fee patent year 05 | 19.08.2022 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2012106540 (IRM LLC [US], et al) [Y] 1-13 * page 1, paragraph 2 * * claims 1-19 * * example 1 *; | [Y]WO2015081813 (SHANGHAI HANSOH BIOMEDICAL CO LTD [CN]) [Y] 1-13 * claims 1-12 *; | [YD]WO2015130014 (KOREA RES INST CHEM TECH [KR]) [YD] 1-13 * claims 1-10 * * page 3, lines 25-30 * * examples 1-3, 10-11, 18 *; | [Y] - THOMAS H. MARSILJE ET AL, "Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro- N 2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)- N 4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 a", JOURNAL OF MEDICINAL CHEMISTRY, (20130725), vol. 56, no. 14, doi:10.1021/jm400402q, ISSN 0022-2623, pages 5675 - 5690, XP055145299 [Y] 1-13 * abstract * * Scheme 2, compound 17e * * page 5679; table 1 * DOI: http://dx.doi.org/10.1021/jm400402q | [Y] - KANG CHUNG HYO ET AL, "Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer", CANCER LETTERS, NEW YORK, NY, US, (20160226), vol. 374, no. 2, doi:10.1016/J.CANLET.2016.02.009, ISSN 0304-3835, pages 272 - 278, XP029445802 [Y] 1-13 * abstract * * page 274; figure 1 * * page 274; tables 1-2 * * Section "Discussion", pages 276-278 * DOI: http://dx.doi.org/10.1016/j.canlet.2016.02.009 | by applicant | US5093330 | US8039479 | WO2015130014 | - PULFORD, Cell. Mol. Life. Sci., (20040000), vol. 61, pages 2939 - 2953 | - ROSKOSKI, Pharmacological Research, (20130000), vol. 68, pages 68 - 94 | - M. CAIRA et al., J. Pharmaceut. Sci., (20040000), vol. 93, no. 3, pages 601 - 611 | - VAN TONDER et al., AAPS Pharm. Sci. Tech., (20040000), vol. 5, no. 1 | - A.L. BINGHAM et al., Chem. Commun., (20010000), vol. 603-604 |